New combination treatment enables targeting of non-responsive lung tumours
The newly identified KRAS G12C inhibitor, with SHP2 inhibition, sensitises tumours to immune checkpoint blockade.
List view / Grid view
A drug target is anything within a living organism to which a drug is directed and/or binds, resulting in a change in its behaviour or function.
The newly identified KRAS G12C inhibitor, with SHP2 inhibition, sensitises tumours to immune checkpoint blockade.
In this in-depth Q&A, Mutlu Dogruel, Vice President of AI at Cresset shares his insights surrounding chatbots, retrieval augmented generation and AI hallucinations, to open up new possibilities for innovation in pharmaceutical research.
Following high-throughput drug screening of the tumour organoids, an effective FDA-approved treatment was identified.
Researchers have identified over 3,000 harmful genetic changes that could disrupt normal RAD51C function.
ICR researchers have discovered that prostate cancer patients with high BCL2 levels have a shorter overall survival rate.
In this Q&A, Revolo Biotherapeutics’ CEO, Woody Bryan, discusses how ‘1104, the Company’s lead candidate for allergic diseases, shifts the immune system from a pro-inflammatory state to a homeostatic state, offering potential remission for allergic conditions. We delve into its unique mechanism of action, supported by preclinical and clinical findings.…
The humanised antibody, Hv1Lt1, showed promising results in pancreatic cancer mouse models.
This study is first to demonstrate with statistical certainty that human visceral adipose tissue accumulated in the abdominal cavity secretes more extracellular vesicles.
Targeting the epigenetic states of specific retroelements in the human genome could mitigate the biological effects of ageing.
A new class of RNAs packed into extracellular vesicles have potential as biomarkers for prostate cancer and other diseases.
Researchers have developed a new AI tool which recognises that protein behaviour can vary by cell and by tissue type.
Genome and transcriptome sequencing revealed that subtypes such as TCF3/4::HLF were associated with an increased risk of relapse.
We had the privilege of speaking to Dr Mark R. Kelley, Associate Director of Basic Science at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center, and Betty and Earl Herr Professor in Pediatric Oncology Research, prior to his talk at PharmSci 360 in 2024. He elucidates what makes…
In this Q&A, Dr Ronald DePinho of MD Anderson elucidates their preclinical proof-of-concept that adjusting TERT levels could be a viable therapeutic approach for mitigating age-related diseases, such as cancer, heart disease and Alzheimer’s.
2 August 2024 | By Eurofins Discovery
In this webinar, we will present how challenging recombinant protein such as GPCRs are produced and characterised and how biophysics participates in GPCRs hit finding and hit confirmation.